Legend Biotech (NASDAQ:LEGN) Now Covered by Analysts at Cantor Fitzgerald

Cantor Fitzgerald started coverage on shares of Legend Biotech (NASDAQ:LEGNFree Report) in a report published on Wednesday, MarketBeat Ratings reports. The brokerage issued an overweight rating and a $82.00 target price on the stock.

Several other brokerages also recently issued reports on LEGN. Barclays raised their price objective on shares of Legend Biotech from $93.00 to $94.00 and gave the stock an overweight rating in a research note on Wednesday, January 24th. Scotiabank initiated coverage on shares of Legend Biotech in a research report on Tuesday, December 19th. They set a sector perform rating and a $65.00 target price on the stock. HC Wainwright reaffirmed a buy rating and set a $87.00 target price on shares of Legend Biotech in a research report on Monday. Raymond James initiated coverage on shares of Legend Biotech in a research report on Wednesday, March 13th. They set an outperform rating and a $86.00 target price on the stock. Finally, UBS Group raised their target price on shares of Legend Biotech from $76.00 to $81.00 and gave the stock a buy rating in a research report on Monday, March 18th. Two equities research analysts have rated the stock with a hold rating and twelve have given a buy rating to the company. Based on data from MarketBeat.com, Legend Biotech has a consensus rating of Moderate Buy and an average price target of $82.70.

Check Out Our Latest Report on Legend Biotech

Legend Biotech Stock Down 0.1 %

Shares of NASDAQ LEGN opened at $56.38 on Wednesday. The company has a debt-to-equity ratio of 0.22, a current ratio of 6.92 and a quick ratio of 6.83. The company has a market cap of $10.26 billion, a P/E ratio of -38.09 and a beta of 0.01. Legend Biotech has a 1 year low of $45.90 and a 1 year high of $77.32. The firm has a 50-day simple moving average of $60.52 and a two-hundred day simple moving average of $61.88.

Legend Biotech (NASDAQ:LEGNGet Free Report) last announced its quarterly earnings data on Monday, March 11th. The company reported ($0.40) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.70) by $0.30. The business had revenue of $76.50 million during the quarter, compared to the consensus estimate of $95.63 million. Legend Biotech had a negative net margin of 181.75% and a negative return on equity of 37.19%. The business’s revenue was up 177.2% on a year-over-year basis. Research analysts anticipate that Legend Biotech will post -1.39 earnings per share for the current year.

Hedge Funds Weigh In On Legend Biotech

Several institutional investors and hedge funds have recently bought and sold shares of LEGN. BluePath Capital Management LLC purchased a new position in Legend Biotech in the third quarter worth $32,000. American International Group Inc. acquired a new stake in shares of Legend Biotech during the second quarter worth $33,000. Lazard Asset Management LLC acquired a new stake in shares of Legend Biotech during the fourth quarter worth $33,000. Coppell Advisory Solutions LLC acquired a new stake in shares of Legend Biotech during the second quarter worth $41,000. Finally, Quarry LP acquired a new stake in shares of Legend Biotech during the fourth quarter worth $45,000. 70.89% of the stock is owned by hedge funds and other institutional investors.

About Legend Biotech

(Get Free Report)

Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery, development, manufacturing, and commercialization of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multiple myeloma (MM).

Featured Stories

Analyst Recommendations for Legend Biotech (NASDAQ:LEGN)

Receive News & Ratings for Legend Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Legend Biotech and related companies with MarketBeat.com's FREE daily email newsletter.